2025 AMA Research Challenge – Member Premier Access

October 22, 2025

Virtual only, United States

Would you like to see your presentation here, made available to a global audience of researchers?
Add your own presentation or have us affordably record your next conference.

Non-small cell lung cancer (NSCLC), constituting about 85% of lung cancer cases, has a notably high incidence in Kentucky. Recent advancements have improved 5-year survival rates from a dismal 9.7% to approximately 18.4% with the introduction of combination chemotherapy and immune checkpoint inhibitors (ICIs) in 2018. Despite these gains, resistance to this combined therapy remains a significant issue. A proposed mechanism for such resistance involves CD73+ myeloid-derived suppressor cells (MDSCs), which may be induced by prostaglandin E2 (PGE2) accumulation following chemotherapy. This study investigates the pathway through which platinum-based chemotherapy agents induce PGE2 overproduction, leading to the development of CD73+ MDSCs. We hypothesize that chemotherapy increases fatty acid synthase (FAS) activity, which elevates arachidonic acid (AA) levels. AA is a substrate for PGE2 synthesis, and its increased availability stimulates the NF-κB/CREB pathway, enhancing COX-2 activity and PGE2 production. The accumulated PGE2 is then thought to drive the formation of CD73+ MDSCs, which contribute to immunotherapy resistance by producing adenosine that suppresses T-cell activity. Our findings, based on mass spectrometry, western blot analysis, and ELISA assays, demonstrate that chemotherapy significantly increases AA levels and activates the enzyme cascade responsible for PGE2 production. Mass spectrometry showed a doubling of AA concentration in chemotherapy-treated LLC cells compared to controls. Western blot analysis revealed enhanced FAS, NF-κB, and CREB activity in chemotherapy-treated KP cells. ELISA results indicated a marked increase in PGE2 levels in the supernatants of cisplatin-treated cells, even with PTGES knockdown, confirming the link between chemotherapy and elevated PGE2 levels. Additionally, flow cytometry analysis in NSCLC mouse models revealed that chemotherapy treatment increased the percentage of CD73+ MDSCs from 10% to 20%. These results confirm that chemotherapy drives the overproduction of PGE2 and contributes to the expansion of CD73+ MDSCs, which may play a critical role in the resistance to immunotherapy. These insights could guide the development of targeted strategies to overcome resistance and improve therapeutic outcomes in NSCLC.

Next from 2025 AMA Research Challenge – Member Premier Access

From Algorithms to Agriculture: Applying AI Methods to Predict Kidney Disease in Farmworkers

From Algorithms to Agriculture: Applying AI Methods to Predict Kidney Disease in Farmworkers

2025 AMA Research Challenge – Member Premier Access

Yusuf Ashktorab

22 October 2025

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Presentations
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2025 Underline - All rights reserved